• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution

FDA Releases COVID-19 Response At-A-Glance Summary

americanpharmaceuticalreviewSeptember 17, 2020

Tag: FDA , COVID-19 , Response At-A-Glance

The U.S. Food and Drug Administration (FDA), along with other federal, state, and local agencies and public health officials across the country, continues critical work to protect public health during the pandemic of COVID-19. To help track updates, the FDA has released a “Response At-A-Glance” document.

Major focus areas of the FDA’s response include increasing the availability of tests, therapeutics, and other devices such as ventilators and personal protective equipment, and many other important items necessary for the response. The FDA is also monitoring the human and animal food supply and taking swift action on fraudulent COVID-19 products.

Previous:Australia enters $1.2bn Covid-19 vaccine supply agreement

Next:Liminal BioSciences Resubmits BLA for Ryplazim for Congenital Plasminogen Deficiency

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

FDA Releases COVID-19 Response At-A-Glance Summary | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

Diosmin(CEP FDA GMP)

Diosmin(CEP FDA GMP)
Bumetanide (FDA)

Bumetanide (FDA)
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Irinotecan (FDA)

Irinotecan (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Nabumetone (FDA)

Nabumetone (FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Etoposide( FDA)

Etoposide( FDA)
Meclozine HCL (FDA)

Meclozine HCL (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service